CDK4 and neoplasm: Targeted therapy can overcome intrinsic tumor resistance by inhibiting signaling pathways such as MAPK, WNT-β-catenin, CDK4-CDK6, or PTEN, while also suppressing local therapy-induced VEGF expression, thereby reducing tumor angiogenesis (39).